AI Article Synopsis
- The incidence of papillary thyroid cancer (PTC) is increasing, but the underlying mechanisms are not well understood, particularly regarding the role of the transcription factor NR4A1.
- High levels of NR4A1 are linked to worse survival rates in PTC patients, and reducing NR4A1 levels slows down the growth of PTC cells by affecting the LEF1 gene.
- NR4A1 interacts with the LEF1 promoter, influencing histone modifications and gene activation, suggesting it may play a significant role in the development and progression of PTC.
Article Abstract
The morbidity of papillary thyroid cancer (PTC) is on the rise, but its pathogenesis is still poorly understood. NR4A1 is a transcription factor primarily involving a wide range of pathophysiological responses, but its relationship with PTC malignancy remains unclear. This study demonstrates that high NR4A1 expression is strongly associated with poor survival outcomes in PTC patients. The depletion of NR4A1 significantly inhibited the proliferation of PTC cells by negating the LEF1-mediated oncogenic alteration. Mechanistically, NR4A1 directly binds to the promoter region of LEF1 and leads to crosstalk with histone acetylation and DNA demethylation to transcriptionally upregulate LEF1 expression, subsequently promoting downstream growth-related genes expressions in PTC. In the light of our findings, NR4A1 may be an emerging driving factor in PTC pathogenesis and progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810957 | PMC |
| http://dx.doi.org/10.1038/s41420-022-00843-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!